UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 264

Sortiert nach

Implementation and Outcomes of a Pilot Collaborative Surgical Hydrocele Training in Côte d'Ivoire

The American journal of tropical medicine and hygiene, 2024-01, Vol.110 (1), p.194

2024

Volltextzugriff (PDF)

Identification of biomarker candidates for filarial parasite infections by analysis of extracellular vesicles

Frontiers in parasitology, 2023-10, Vol.2

2023

Volltextzugriff (PDF)

Geospatial modelling of lymphatic filariasis and malaria co-endemicity in Nigeria

International health, 2023-09, Vol.15 (5), p.566-572

2023

Volltextzugriff (PDF)

Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d'Ivoire: A randomized controlled superiority study

PLoS neglected tropical diseases, 2023-09, Vol.17 (9), p.e0011633-e0011633

2023

Volltextzugriff (PDF)

The proteome of extracellular vesicles of the lung fluke Paragonimus kellicotti produced in vitro and in the lung cyst

Scientific reports, 2023-08, Vol.13 (1), p.13726-13726, Article 13726

2023

Volltextzugriff (PDF)

Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis

PLoS neglected tropical diseases, 2023-08, Vol.17 (8), p.e0011567-e0011567

2023

Volltextzugriff (PDF)

IgG4 antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis

PLoS neglected tropical diseases, 2023-06, Vol.17 (6), p.e0011364-e0011364

2023

Volltextzugriff (PDF)

A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole

PLoS neglected tropical diseases, 2023-05, Vol.17 (5)

2023

Volltextzugriff (PDF)

A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole for treatment of onchocerciasis

PLoS neglected tropical diseases, 2023-05, Vol.17 (5)

2023

Volltextzugriff (PDF)

A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis

PLoS neglected tropical diseases, 2023-05, Vol.17 (5), p.e0011365-e0011365

2023

Volltextzugriff (PDF)

Histopathological evaluation of Onchocerca volvulus nodules by microscopy and by digital image analysis for the study of macrofilaricidal drug efficacy

Frontiers in medicine, 2023-02, Vol.10, p.1099926-1099926

2023

Volltextzugriff (PDF)

A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination

Journal of clinical virology plus, 2023-02, Vol.3 (1), p.100135-100135, Article 100135

2023

Volltextzugriff (PDF)

Direct Proteomic Detection and Prioritization of 19 Onchocerciasis Biomarker Candidates in Humans

Molecular & cellular proteomics, 2023-01, Vol.22 (1), p.100454-100454, Article 100454

2023

Volltextzugriff (PDF)

Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa

PLoS neglected tropical diseases, 2022-12, Vol.16 (12), p.e0010953-e0010953

2022

Volltextzugriff (PDF)

Persistence of onchocerciasis in villages in Enugu and Ogun states in Nigeria following many rounds of mass distribution of ivermectin

BMC infectious diseases, 2022-11, Vol.22 (1), p.1-832, Article 832

2022

Volltextzugriff (PDF)

Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial

The Lancet infectious diseases, 2022-08, Vol.22 (8), p.1200-1209

2022

Volltextzugriff (PDF)

Comparative proteomics of adult Paragonimus kellicotti excretion/secretion products released in vitro or present in the lung cyst nodule

PLoS neglected tropical diseases, 2022-08, Vol.16 (8), p.e0010679-e0010679

2022

Volltextzugriff (PDF)

Semiannual Treatment of Albendazole Alone is Efficacious for Treatment of Lymphatic Filariasis: A Randomized Open-label Trial in Cote d’Ivoire

Clinical infectious diseases, 2022-07, Vol.74 (12), p.2200-2208

2022

Volltextzugriff (PDF)

Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia

Acta tropica, 2022-07, Vol.231, p.106437-106437, Article 106437

2022

Volltextzugriff (PDF)

Complementary and alternative medicine exposure in oncology (CAMEO) study: A multi-institutional cross-sectional analysis of patients receiving cancer treatment

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e18739-e18739

2022

Volltextzugriff (PDF)

Shifting perceptions of alternative therapies in cancer patients during the COVID-19 pandemic: Results from the Complementary and Alternative Medicine Exposure in Oncology (CAMEO) Study

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.e24130-e24130

2022

Volltextzugriff (PDF)

Development and Introduction of the Filariasis Test Strip: A New Diagnostic Test for the Global Program to Eliminate Lymphatic Filariasis

The American journal of tropical medicine and hygiene, 2022-05, Vol.106 (5_Suppl), p.56-60

2022

Volltextzugriff (PDF)

Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis

The American journal of tropical medicine and hygiene, 2022-05, Vol.106 (5_Suppl), p.13-17

2022

Volltextzugriff (PDF)

Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis

The American journal of tropical medicine and hygiene, 2022-05, Vol.106 (5_Suppl), p.18-25

2022

Volltextzugriff (PDF)

Characterization of a novel microfilarial antigen for diagnosis of Wuchereria bancrofti infections

PLoS neglected tropical diseases, 2022-05, Vol.16 (5), p.e0010407-e0010407

2022

Volltextzugriff (PDF)

1 – 25 von 264

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(255)
Mit Volltextzugriff
(230)

Publikationsform

Sprache

Englisch
(264)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Science & Technology
(213)
Life Sciences & Biomedicine
(199)
Humans
(138)
Animals
(131)
Tropical Medicine
(103)
Infectious Diseases
(101)
Female
(92)
Parasitology
(90)
Male
(89)
Biological And Medical Sciences
(67)
Adult
(65)
Filariasis
(59)
Tropical Diseases
(59)
Medical Sciences
(51)
Public, Environmental & Occupational Health
(48)
Middle Aged
(47)
Parasitic Diseases
(47)
Elephantiasis, Filarial - Drug Therapy
(45)
Infections
(42)
Adolescent
(40)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Implementation and Outcomes of a Pilot Collaborative Surgical Hydrocele Training in Côte d'Ivoire

Identification of biomarker candidates for filarial parasite infections by analysis of extracellular vesicles

Geospatial modelling of lymphatic filariasis and malaria co-endemicity in Nigeria

Safety and tolerability of moxidectin and ivermectin combination treatments for lymphatic filariasis in Côte d'Ivoire: A randomized controlled superiority study

The proteome of extracellular vesicles of the lung fluke Paragonimus kellicotti produced in vitro and in the lung cyst

Pharmacokinetics of Moxidectin combined with Albendazole or Albendazole plus Diethylcarbamazine for Bancroftian Filariasis

IgG4 antibodies to the recombinant filarial antigen Wb-Bhp-1 decrease dramatically following treatment of lymphatic filariasis

A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole

A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole for treatment of onchocerciasis

A randomized, open-label study of the tolerability and efficacy of one or three daily doses of ivermectin plus diethylcarbamazine and albendazole (IDA) versus one dose of ivermectin plus albendazole (IA) for treatment of onchocerciasis

Histopathological evaluation of Onchocerca volvulus nodules by microscopy and by digital image analysis for the study of macrofilaricidal drug efficacy

A simple point-of-care assay accurately detects anti-spike antibodies after SARS-CoV-2 vaccination

Direct Proteomic Detection and Prioritization of 19 Onchocerciasis Biomarker Candidates in Humans

Comparing antigenaemia- and microfilaraemia as criteria for stopping decisions in lymphatic filariasis elimination programmes in Africa

Persistence of onchocerciasis in villages in Enugu and Ogun states in Nigeria following many rounds of mass distribution of ivermectin

Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial

Comparative proteomics of adult Paragonimus kellicotti excretion/secretion products released in vitro or present in the lung cyst nodule

Semiannual Treatment of Albendazole Alone is Efficacious for Treatment of Lymphatic Filariasis: A Randomized Open-label Trial in Cote d’Ivoire

Community-based trial assessing the impact of annual versus semiannual mass drug administration with ivermectin plus albendazole and praziquantel on helminth infections in northwestern Liberia

Complementary and alternative medicine exposure in oncology (CAMEO) study: A multi-institutional cross-sectional analysis of patients receiving cancer treatment

Shifting perceptions of alternative therapies in cancer patients during the COVID-19 pandemic: Results from the Complementary and Alternative Medicine Exposure in Oncology (CAMEO) Study

Development and Introduction of the Filariasis Test Strip: A New Diagnostic Test for the Global Program to Eliminate Lymphatic Filariasis

Lessons from Large-Scale Tolerability and Acceptability Studies of Triple Drug Mass Drug Administration Performed to Support Policy Change and Accelerate Elimination of Lymphatic Filariasis

Country Reports on Practical Aspects of Conducting Large-Scale Community Studies of the Tolerability of Mass Drug Administration with Ivermectin/Diethylcarbamazine/Albendazole for Lymphatic Filariasis

Characterization of a novel microfilarial antigen for diagnosis of Wuchereria bancrofti infections

Suchergebnisse filtern